|Bid||0.0000 x 1200|
|Ask||0.0000 x 1100|
|Day's Range||0.8400 - 0.8800|
|52 Week Range||0.7000 - 2.6900|
|Beta (5Y Monthly)||1.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.33|
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
WATERTOWN, Mass., May 26, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.
EyePoint Pharmaceuticals, Inc. (EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of positive retrospective case study data supporting DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery. The data were presented in three electronic posters and one oral paper session at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting on May 16-17, 2020. The ongoing retrospective study is designed to provide large-scale, real-world data from surgeons based on their early experiences with DEXYCU.
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.00% and 7.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) were flat in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share were up 45.00% year over year to ($0.11), which missed the estimate of ($0.10).Revenue of $7,489,000 higher by 272.22% year over year, which beat the estimate of $7,250,000.Outlook Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 06, 2020View more earnings on EYPTWebcast URL: https://edge.media-server.com/mmc/p/wmbgnxa6Technicals 52-week high: $2.6952-week low: $0.70Price action over last quarter: down 30.08%Company Profile EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed 5 FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.See more from Benzinga * Sally Beauty Holdings: Q2 Earnings Insights * Recap: Radware Q1 Earnings * Meet Group: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Total revenues of $7.5 million and net product revenues of $4.7 million - - Cash conservation and reorganization initiatives coupled with recent financings.
WATERTOWN, Mass., April 29, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.
One of the industry’s highly watched neuroscience drugmakers is cutting more than half of its workforce as it works to revive hope for its sophomore drug candidate and weather a drop in sales.
EyePoint Pharmaceuticals, Inc. (EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has taken proactive measures in response to changing market conditions caused by the novel coronavirus (COVID-19) global pandemic. EyePoint is committed to providing uninterrupted access to our products during the COVID-19 pandemic for those patients who are in essential need of treatment.
Buckle up, we’re in for a bumpy ride. The number of new coronavirus (COVID-19) cases continues to surge, and as such, the market’s volatility has persisted. Following up the drop on March 27, stocks started off the week by gaining on the lockdown extension in the U.S. While the movements in yesterday’s session were less extreme than we’ve become accustomed to seeing, it remains unclear when the market will hit bottom.Against this backdrop, it’s easy to understand why some investors have been sent running for the hills. However, thrill-seeking Wall Street observers see exciting opportunities as the market whipsaws. To find names that can deliver solid returns and now come with a bargain price tag, these investors will often turn to penny stocks, or those trading for less than $5 per share.Sure, there could be a very good reason these tickers are so affordable, but should there be even minor share price appreciation, massive percentage gains could materialize, along with hefty profits for investors.Bearing this in mind, we pulled up the database from TipRanks to find three penny stocks the analysts believe look compelling despite the risk involved. Not to mention the platform revealed that each of these Buy-rated names could see upside growth landing in the triple digits.MannKind Corporation (MNKD)Over the past three decades, MannKind has been developing therapeutic products and technologies to improve the lives of patients all over the world. Like the broader market, 2020 has not been kind to this company, but at $1.04, several analysts argue that now is the time to snap up shares.Part of the excitement surrounding this healthcare name came after it announced on March 17 that it’s taking on COVID-19. According to management, the company will shift the focus of its R&D pipeline to new compounds that could reduce the morbidity and mortality caused by respiratory viral infections like COVID-19. In a collaboration with Immix Biopharma, MNKD will design a dry powder formulation of a compound to treat one of the complications of COVID-19, acute respiratory distress syndrome. Right now, the priority is to develop a proof of concept, and after, it will be evaluated to see if it’s an effective treatment.On top of this, Cantor Fitzgerald’s Brandon Folkes notes, “MNKD continues to have excess manufacturing capacity which it can leverage to assist other companies in meeting any increased demand due to the outbreak.”As a result, the analyst maintained both his Overweight call and $3 price target. Should the target be met, shares stand to soar 178% in the next year. (To watch Folkes’ track record, click here)As for its currently available products, Afrezza has generated impressive sales. During the fourth quarter, net sales grew 36% quarter-over-quarter to reach $7.8 million. Adding to the good news, the company guided for stable or even improved gross-to-nets in 2020. Weighing in for H.C. Wainwright, analyst Oren Livnat states management’s outlook “gives us confidence in the underlying translation of Rx growth to sales growth going forward, and the latest prescription trends show over 30% year-over-year insulin-unit-based growth despite fewer free scripts.”Livnat adds, “Separately, there is increasing investor interest in TreT-- Technosphere treprostinil--partnered with United Therapeutics...Assuming positive progress, it should bring in another $25 million in 2020 milestones, bringing total payments from United to about $100 million. MannKind would get double-digit royalties on this next generation version of United’s Tyvaso, which is running at about $450 million sales now.”It should come as no surprise, then, that Livnat reiterated his bullish call and $2.50 price target. (To watch Livnat’s track record, click here)Overall, with 100% Street support, the consensus is unanimous: MNKD is a Strong Buy. Additionally, the $2.67 average price target puts the upside potential at 157%. (See MannKind stock analysis on TipRanks)EyePoint Pharmaceuticals (EYPT)This biopharma company is committed to developing products for patients suffering from serious eye disorders. As each share is currently going for $1.02, EyePoint’s price tag could present investors with an attractive entry point.Following its fourth quarter earnings release, this is the stance taken by Guggenheim analyst Dana Flanders. Net sales of $8.6 million, which came in above his prediction, were fueled by strong demand for Dexycu and Yutiq as they’ve seen momentum continue to accelerate.Flanders commented, “Notably, we are encouraged by strong underlying demand for Dexycu and Yutiq, for which EYPT reported increases of 111% and 59%, respectively, compared to 3Q19...While we believe the increase in repeat order volumes shows solid adoption, we see room for further continued growth opportunities to expand Dexycu into new accounts where the company is actively negotiating agreements with additional GPOs while Yutiq still has ample runway to expand (58% of target account list unpenetrated).”It should also be noted that back in February, EYPT signed an exclusive license agreement with Equinox Science to develop an anti-VEGF TKI (Vorolanib) that uses EYPT’s Durasert sustained release technology for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR) and retinal vein occlusion (RVO). The candidate, EYP-1901, could improve the safety profile for Vorolanib. While Flanders doesn’t factor EYP-1901 into his model as it’s still in the early stages of development, he thinks it reflects a “compelling long-term opportunity."Expounding on this, he said, “Although there are multiple long-acting agents in development, wet AMD is a multi-billion dollar market (Lucentis, Eylea, etc.), and we view Phase 1 data as an important catalyst for EYPT shares.”Based on all of the above, Flanders stayed with the bulls. Along with his Buy recommendation, he left the $4 price target unchanged, implying 296% upside potential. (To watch Flanders’ track record, click here)What does the rest of the Street have to say? Out of 4 recent reviews, 3 were bullish, making the consensus rating a Strong Buy. At $4.33, the average price target is more aggressive than Flanders’ and brings the upside potential to 329%. (See EyePoint stock analysis on TipRanks)iAnthus Capital Holdings (ITHUF)Switching gears now, iAnthus inhabits the cannabis space and has created several cannabis brands as well as a network of cannabis operations. With the broader market’s sell-off pushing shares down to $0.56 apiece, some members of the Street believe there’s a unique opportunity to get in on the action.Ahead of its upcoming fourth quarter earnings release, the future looks bright if you ask Stifel analyst Robert Fagan. Thanks to three new store openings in Florida, which could have led to gross margin expansion in Q4, sales are expected to hit $27 million, representing a 20% quarter-over-quarter gain.As for profitability, the result stands to be even better. Despite the fact that lower overall market growth in Nevada and New York and the slight network expansion delay in Florida and Massachusetts could weigh down 2020 sales, Fagan has high hopes when it comes to the bottom-line number. While Q4 EBITDA is slated to come in at a loss of $3 million, this is up from -$4 million in Q3 and higher than the Street’s -$6 million call.With respect to 2021 sales, Fagan thinks the figure will land at $376 million, which if achieved, puts year-over-year growth at 70%. This in tandem with increasing operating leverage from the expanded scale should result in EBITDA of $114 million on margins of 30%, a year-over-year boost of 800 basis points.The source of these potential wins? Fagan notes, “We expect ITHUF to continue to invest in Florida, given its solid 4% market share, and steady stream of new store openings over the past year (~1/month), a trend we believe will continue. In Massachusetts, we expect ITHUF’s two production facilities and two REC stores to be fully operational in 2021, enabling good market share capture and growth.” The analyst also mentions that its first mover advantage in New Jersey bodes well for the cannabis company.Fagan concludes, “We note its gross margin profile is already in line with its larger peers, presenting a possible quick path forward toward profitability upon realization of higher volumes.”It makes sense, then, that Fagan kept a Buy rating on the stock. However, he did drop the price target to $2.47, but this still leaves room for a 340% twelve-month rise. (To watch Fagan’s track record, click here)Looking at the consensus breakdown, 2 Buys and 1 Hold published in the last three months add up to a Moderate Buy Street consensus. Based on the $1.96 average price target, shares could skyrocket 266% in the next twelve months. (See iAnthus stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 25.00% and 12.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
– Total revenues of $8.6 million in Q4 2019 and $20.4 million for full year 2019 – – Net product revenues of $7.9 million in Q4 2019 and $16.8 million for full year 2019 –.
EyePoint Pharmaceuticals, Inc. (EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced positive topline 36-month follow-up data from the second Phase 3 trial of YUTIQ®(fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
WATERTOWN, Mass., Feb. 27, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic.
EyePoint Pharmaceuticals, Inc. (EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $1.45 per share. The gross proceeds of the offering to the Company are expected to be approximately $21,750,000, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, EyePoint granted the underwriters a thirty-day option to purchase up to an additional 2,250,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
EyePoint Pharmaceuticals, Inc. (EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by EyePoint. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
EyePoint Pharmaceuticals, Inc. (EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Vision Center Network of America, LLC (“VCNA”), a Clinically Integrated Network (“CIN”) with the aim of significantly improving the healthcare delivery system in the specialty area of ophthalmic surgery, today announced that they have entered into an purchase agreement for DEXYCU® (dexamethasone intraocular suspension) 9% for its network of nine surgery centers located in New York and New Jersey that perform an estimated 60,000 cataract procedures annually. The agreement will enable VCNA physicians to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences ...
EyePoint Pharmaceuticals, Inc. (EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has signed an exclusive license agreement with Equinox Science, LLC, to develop vorolanib, a tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration (wAMD), diabetic retinopathy (DR) and retinal vein occlusion (RVO). Vorolanib is being developed as EYP-1901 utilizing Eyepoint’s bioerodible Durasert technology, a miniaturized, injectable, sustained-release intravitreal drug delivery system with a 6-month duration.
EyePoint Pharmaceuticals, Inc. (EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a fast-growing ophthalmology focused pharmaceutical company in China, today announced an exclusive license agreement for the development and commercialization of DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in Mainland China, Hong Kong, Macau and Taiwan. DEXYCU is currently marketed by EyePoint in the U.S. EyePoint maintains worldwide development and commercialization rights outside of the territories licensed to Ocumension.
For the fourth quarter ended December 31, 2019, total revenues are estimated to be between $7.5 and $8.2 million and net product revenues are estimated to be between $6.9 and $7.6 million, a significant acceleration from net product revenues of $1.0 million reported for the third quarter ended September 30, 2019. For the full-year 2019, total revenues are estimated to be between $19.3 and $20.0 million and net product revenues are estimated to be between $15.8 and $16.5 million.